{"id":"vec","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL5440259","moleculeType":null,"molecularWeight":"447.49"},"_dailymed":{"setId":"b012b1b1-9e59-4525-8f4d-dae98344d15f","title":"VECURONIUM BROMIDE INJECTION, POWDER, FOR SOLUTION [PHLOW CORP.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VEC (developed by Centre Leon Berard) is designed to activate T-cell mediated immunity against cancer by presenting tumor antigens to the immune system. As a marketed therapeutic vaccine, it works by priming the body's adaptive immune response to target malignant cells, potentially used in combination with other immunotherapies or as monotherapy depending on the indication.","oneSentence":"VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:56:20.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (advanced or metastatic)"}]},"trialDetails":[{"nctId":"NCT02923778","phase":"PHASE2","title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-31","conditions":"Leiomyosarcoma, Liposarcoma, Sarcoma G2","enrollment":40},{"nctId":"NCT02978625","phase":"PHASE2","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-27","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma","enrollment":68},{"nctId":"NCT06834035","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-08-04","conditions":"Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa","enrollment":8},{"nctId":"NCT07482176","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2026-03-16","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07102394","phase":"PHASE1","title":"Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02","conditions":"NF1, Neurofibromatosis, Cutaneous Neurofibroma","enrollment":10},{"nctId":"NCT04645212","phase":"","title":"Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-12-14","conditions":"Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":23},{"nctId":"NCT04163952","phase":"PHASE1","title":"Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-01-31","conditions":"Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma","enrollment":5},{"nctId":"NCT07136285","phase":"PHASE1, PHASE2","title":"Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC","status":"RECRUITING","sponsor":"Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-07-24","conditions":"SCLC, Extensive Stage","enrollment":27},{"nctId":"NCT06856577","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2025-02-28","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT02965716","phase":"PHASE2","title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-05","conditions":"Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7","enrollment":43},{"nctId":"NCT03069378","phase":"PHASE2","title":"A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-03-03","conditions":"Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma","enrollment":41},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT03802604","phase":"EARLY_PHASE1","title":"Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2018-12-10","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT04418427","phase":"PHASE2","title":"ADVM-022 Intravitreal Gene Therapy for DME","status":"COMPLETED","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-05-28","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":36},{"nctId":"NCT07011589","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)","status":"NOT_YET_RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-07","conditions":"Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa","enrollment":18},{"nctId":"NCT03554044","phase":"PHASE1","title":"T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-02-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":20},{"nctId":"NCT05038150","phase":"PHASE1, PHASE2","title":"Study of SGN1 in Patients With Advanced Solid Tumor","status":"RECRUITING","sponsor":"Guangzhou Sinogen Pharmaceutical Co., Ltd","startDate":"2023-01-16","conditions":"Advanced Solid Tumor","enrollment":70},{"nctId":"NCT05103345","phase":"PHASE1, PHASE2","title":"Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor","status":"RECRUITING","sponsor":"Guangzhou Sinogen Pharmaceutical Co., Ltd","startDate":"2023-04-19","conditions":"Advanced Solid Tumor","enrollment":70},{"nctId":"NCT06286956","phase":"NA","title":"Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vecmedical Spain, S.L.","startDate":"2021-04-19","conditions":"Rectal Polyp, Rectal Polyps, Rectal Lesion","enrollment":40},{"nctId":"NCT04330430","phase":"PHASE2","title":"Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-09-08","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":24},{"nctId":"NCT02819843","phase":"PHASE2","title":"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-06-21","conditions":"Melanoma, Merkel Cell Carcinoma, Other Solid Tumors","enrollment":19},{"nctId":"NCT03086642","phase":"PHASE1","title":"Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer","status":"COMPLETED","sponsor":"Karie D. Runcie, MD","startDate":"2017-11-16","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT03663712","phase":"PHASE1","title":"Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies","status":"COMPLETED","sponsor":"Dan Blazer III, M.D.","startDate":"2019-05-23","conditions":"Peritoneal Surface Malignancy","enrollment":28},{"nctId":"NCT02509507","phase":"PHASE1, PHASE2","title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-05","conditions":"Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node","enrollment":127},{"nctId":"NCT03300544","phase":"PHASE1","title":"Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-14","conditions":"Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":3},{"nctId":"NCT01740297","phase":"PHASE1, PHASE2","title":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-07","conditions":"Melanoma","enrollment":217},{"nctId":"NCT03842943","phase":"PHASE2","title":"Neoadjuvant Combination Immunotherapy for Stage III Melanoma","status":"RECRUITING","sponsor":"University of Louisville","startDate":"2019-07-03","conditions":"Cutaneous Melanoma","enrollment":28},{"nctId":"NCT02265770","phase":"PHASE2, PHASE3","title":"An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2015-06-02","conditions":"Childhood Ependymoma","enrollment":536},{"nctId":"NCT04917874","phase":"PHASE3","title":"A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Krystal Biotech, Inc.","startDate":"2021-05-25","conditions":"Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa","enrollment":47},{"nctId":"NCT03206073","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-07","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma","enrollment":34},{"nctId":"NCT04427306","phase":"PHASE2","title":"Neoadjuvant T-VEC in High Risk Early Melanoma","status":"SUSPENDED","sponsor":"University of California, Davis","startDate":"2020-05-21","conditions":"Melanoma","enrollment":6},{"nctId":"NCT04185311","phase":"PHASE1","title":"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-10","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":6},{"nctId":"NCT03064763","phase":"PHASE1","title":"Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-07","conditions":"Unresectable Stage IIIB-IV Malignant Melanoma","enrollment":18},{"nctId":"NCT02890368","phase":"PHASE1","title":"Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-09","conditions":"Solid Tumors, Mycosis Fungoides, Melanoma","enrollment":56},{"nctId":"NCT04491604","phase":"PHASE3","title":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","status":"COMPLETED","sponsor":"Krystal Biotech, Inc.","startDate":"2020-08-17","conditions":"Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa","enrollment":31},{"nctId":"NCT02658812","phase":"PHASE2","title":"Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-01","conditions":"Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma","enrollment":11},{"nctId":"NCT02263508","phase":"PHASE3","title":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-12-08","conditions":"Melanoma","enrollment":713},{"nctId":"NCT03921073","phase":"PHASE2","title":"Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-08-20","conditions":"Angiosarcoma of Skin","enrollment":5},{"nctId":"NCT03294083","phase":"PHASE1, PHASE2","title":"A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2018-06-07","conditions":"Renal Cell Carcinoma","enrollment":89},{"nctId":"NCT02977156","phase":"PHASE1","title":"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2017-01-03","conditions":"Metastatic Tumor, Advanced Tumor","enrollment":22},{"nctId":"NCT04849260","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-08-26","conditions":"Local Progression or Metastatic Melanoma With Failed First-line Treatment","enrollment":54},{"nctId":"NCT03458117","phase":"PHASE1","title":"T-VEC in Non-melanoma Skin Cancer","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-04-19","conditions":"Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT04363983","phase":"NA","title":"Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-13","conditions":"Gastrointestinal Neoplasms","enrollment":6300},{"nctId":"NCT02630368","phase":"PHASE1, PHASE2","title":"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","status":"UNKNOWN","sponsor":"Institut Bergonié","startDate":"2015-09-18","conditions":"Solid Tumors, Soft-tissue Sarcoma, Breast Cancer","enrollment":197},{"nctId":"NCT02366195","phase":"PHASE2","title":"Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-04-07","conditions":"Unresected Stage IIIb to IVM1c Melanoma","enrollment":112},{"nctId":"NCT03071094","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"Transgene","startDate":"2017-07-27","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":14},{"nctId":"NCT02173171","phase":"","title":"Registry Study for Talimogene Laherparepvec","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-04-27","conditions":"Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial","enrollment":185},{"nctId":"NCT03555032","phase":"PHASE1, PHASE2","title":"TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2018-06-26","conditions":"Melanoma and Sarcoma","enrollment":15},{"nctId":"NCT04990271","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2021-07-05","conditions":"Retinoblastoma","enrollment":92},{"nctId":"NCT01636284","phase":"PHASE2","title":"A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-06","conditions":"Hepatocellular Carinoma","enrollment":16},{"nctId":"NCT01394939","phase":"PHASE1, PHASE2","title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-01","conditions":"Colorectal Carcinoma, CRC","enrollment":52},{"nctId":"NCT03747744","phase":"PHASE1","title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-09-28","conditions":"Melanoma","enrollment":18},{"nctId":"NCT02562755","phase":"PHASE3","title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","status":"COMPLETED","sponsor":"SillaJen, Inc.","startDate":"2015-10","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":459},{"nctId":"NCT03972046","phase":"PHASE2","title":"Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma","status":"WITHDRAWN","sponsor":"TriHealth Inc.","startDate":"2019-06-24","conditions":"Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin","enrollment":""},{"nctId":"NCT03430687","phase":"PHASE1","title":"Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2018-06-01","conditions":"Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7","enrollment":""},{"nctId":"NCT02830646","phase":"NA","title":"Kidney Function Indexed Extracellular Volume Before and After Obesity Surgery","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-05","conditions":"Obesity","enrollment":14},{"nctId":"NCT00769704","phase":"PHASE3","title":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","status":"COMPLETED","sponsor":"BioVex Limited","startDate":"2009-04","conditions":"Melanoma","enrollment":437},{"nctId":"NCT00402025","phase":"PHASE1","title":"Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"BioVex Limited","startDate":"2006-11","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT00554372","phase":"PHASE2","title":"A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-08","conditions":"Carcinoma, Hepatocellular","enrollment":30},{"nctId":"NCT01169584","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2010-08","conditions":"Neuroblastoma, Rhabdomyosarcoma, Lymphoma","enrollment":6},{"nctId":"NCT01171651","phase":"PHASE2","title":"A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2009-08","conditions":"Carcinoma, Hepatocellular","enrollment":25},{"nctId":"NCT01380600","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2010-07","conditions":"Carcinoma, Colorectal","enrollment":15},{"nctId":"NCT00289016","phase":"PHASE2","title":"A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma","status":"COMPLETED","sponsor":"BioVex Limited","startDate":"2005-12","conditions":"Melanoma","enrollment":50},{"nctId":"NCT02574260","phase":"PHASE2","title":"An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)","status":"COMPLETED","sponsor":"BioVex Limited","startDate":"2008-08","conditions":"Melanoma","enrollment":3},{"nctId":"NCT00625456","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-06","conditions":"Melanoma, Lung Cancer, Renal Cell Carcinoma","enrollment":23},{"nctId":"NCT01387555","phase":"PHASE2","title":"A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-12","conditions":"Hepatocellular Carcinoma, Liver Cancer, HCC","enrollment":129},{"nctId":"NCT00429312","phase":"PHASE1, PHASE2","title":"A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2007-03","conditions":"Melanoma","enrollment":10},{"nctId":"NCT01329809","phase":"PHASE2","title":"Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors","status":"TERMINATED","sponsor":"Jennerex Biotherapeutics","startDate":"2011-10","conditions":"Colorectal Carcinoma","enrollment":2},{"nctId":"NCT00629759","phase":"PHASE1","title":"A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2006-01","conditions":"Neoplasms, Liver","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1754,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vincristine","Etoposide","Cyclophosphamide"],"phase":"marketed","status":"active","brandName":"VEC","genericName":"VEC","companyName":"Centre Leon Berard","companyId":"centre-leon-berard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Colorectal cancer (advanced or metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}